

# The Puerto Rico Chamber of Commerce and El Nuevo Día present:





Transitioning from MANAGED CARE to INTEGRATED CARE






#### **Puerto Rico Health & Insurance Conference 2019**

# TAKEAWAY #1: "Accelerate the Transition from MANAGED CARE to INTEGRATED CARE through Provider PAYMENT REFORM"

### A PAYMENT SYSTEMS: Align incentives between INPATIENT FACILITIES and PROVIDERS.



Risk Agreement Type: **BUNDLE PAYMENT** 

Acute Care Hospital: **HEART VALVE REPLACEMENT Sx.** 

Performance Period: **CY2018**Bonus or Penalty: **15%** (\$4,500)

Procedure Fee: \$15,000

Exp. Episode Price: \$30,000 (Surgery to 90-D post discharge)

Procedures Performed: 25

Recon. Report: 180 and 365-D after performance period ends

Quality Adj. Price:

Below Acceptable \$25,500 Acceptable \$30,000 Good \$32,500

Excellent **\$34,500** 


- Services delivered by multiple providers during a SINGLE EPISODE OF CARE and pre-defined time period.
- SINGLE PAYMENT PER EPISODE across MULTIPLE provider types.



### Puerto Rico Health & Insurance Conference 2019

## TAKEAWAY #2: "Understand COST DRIVERS and CARE GAPS through DATA ANALYTICS"

#### AVG. BREAST CA STAGE IV PATIENT IN PR: 66 Y/O FEMALE








### **Puerto Rico Health & Insurance Conference 2019**

### TAKEAWAY #3: "Accelerate our Understanding of COST-EFFECTIVENESS ANALYSIS to Determine VALUE-BASED SPECIALTY MEDICATION TREND"

#### **HER2-POSITIVE BREAST CA**

Code	Alternative	Cost		Incr	emental Cost	Effectiveness	Incremental Effectiveness	ICE	₹
J9355	TH (Paclitaxel+ Herceptin)	\$	1,516.57	-\$	347.61	16.8%	-39.5%	\$	880
J9355	TCH (Carboplatin+Docetaxel+Herceptin)	\$	1,553.05	\$	-	56.3%	0.0%		-
J9306	THP (Paclitaxel/Docetaxel+ Herceptin+ Perjecta)	\$	1,864.18	\$	311.13	17%	-39.4%	-\$	789.67
J9306	TCHP (Carboplatin+ Docetaxel+ Herceptin+ Perjecta)	\$	1,898.56	\$	345.51	31%	-25%	-\$	1,387.59















www.camarapr.org

#tucamaraenaccion